eicosapentaenoic acid ethyl ester has been researched along with Dyslipidemias in 12 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Though statin therapy is known to slow coronary atherosclerosis progression and reduce cardiovascular (CV) events, significant CV risk still remains." | 3.01 | Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. ( Bhatt, DL; Budoff, MJ; Kinninger, A; Lakshmanan, S; Le Pa, VT; May, HT; Muhlestein, JB; Nelson, JR; Roy, SK; Shaikh, K; Shekar, C; Tayek, J, 2021) |
| "To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service." | 1.72 | Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. ( Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boden, WE | 1 |
| Andersson, C | 1 |
| Michaeli, DT | 1 |
| Michaeli, JC | 1 |
| Boch, T | 1 |
| Michaeli, T | 1 |
| Budoff, MJ | 1 |
| Muhlestein, JB | 1 |
| Bhatt, DL | 1 |
| Le Pa, VT | 1 |
| May, HT | 1 |
| Shaikh, K | 1 |
| Shekar, C | 1 |
| Kinninger, A | 1 |
| Lakshmanan, S | 1 |
| Roy, SK | 1 |
| Tayek, J | 1 |
| Nelson, JR | 1 |
| Pearson, GJ | 1 |
| Thanassoulis, G | 1 |
| Anderson, TJ | 1 |
| Barry, AR | 1 |
| Couture, P | 1 |
| Dayan, N | 1 |
| Francis, GA | 1 |
| Genest, J | 1 |
| Grégoire, J | 1 |
| Grover, SA | 1 |
| Gupta, M | 1 |
| Hegele, RA | 1 |
| Lau, D | 1 |
| Leiter, LA | 1 |
| Leung, AA | 1 |
| Lonn, E | 1 |
| Mancini, GBJ | 1 |
| Manjoo, P | 1 |
| McPherson, R | 1 |
| Ngui, D | 1 |
| Piché, ME | 1 |
| Poirier, P | 1 |
| Sievenpiper, J | 1 |
| Stone, J | 1 |
| Ward, R | 1 |
| Wray, W | 1 |
| Lan, NSR | 1 |
| Fegan, PG | 1 |
| Yeap, BB | 1 |
| Rankin, JM | 1 |
| Watts, GF | 1 |
| Jia, X | 1 |
| Akeroyd, JM | 1 |
| Nasir, K | 1 |
| Nambi, V | 1 |
| Ballantyne, CM | 2 |
| Petersen, LA | 1 |
| Virani, SS | 1 |
| Perez-Martinez, P | 1 |
| Katsiki, N | 1 |
| Mikhailidis, DP | 1 |
| Orringer, CE | 1 |
| Brinton, EA | 1 |
| Bays, HE | 1 |
| Kastelein, JJ | 1 |
| Braeckman, RA | 1 |
| Soni, PN | 1 |
| Reddy, KJ | 1 |
| Chowdhury, S | 1 |
| Fialkow, J | 1 |
| Crandell, JR | 1 |
| Tartaglia, C | 1 |
| Tartaglia, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Face and Content Validation of a Healthcare Professional-facing Toolkit to Communicate Information on the Portfolio Diet and PortfolioDiet.App[NCT05915455] | 30 participants (Anticipated) | Interventional | 2023-07-10 | Recruiting | |||
| Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy[NCT01047501] | Phase 3 | 702 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -2.2 |
| Placebo | 7.1 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -1.8 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.8 |
| Placebo | 6.7 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | 1.5 |
| Placebo | 8.8 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -5.0 |
| Placebo | 9.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.5 |
| Placebo | 5.9 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.1 |
| Placebo | 15.0 |
3 reviews available for eicosapentaenoic acid ethyl ester and Dyslipidemias
| Article | Year |
|---|---|
The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future.
Topics: Biomarkers; Cardiovascular Diseases; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Fatt | 2020 |
Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
Topics: Adult; Aged; Atherosclerosis; Biomarkers; Clinical Decision-Making; Consensus; Dyslipidemias; Eicosa | 2020 |
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Topics: Animals; Cardiovascular Diseases; Chemistry, Pharmaceutical; Cholesterol, LDL; Diet; Dietary Supplem | 2016 |
2 trials available for eicosapentaenoic acid ethyl ester and Dyslipidemias
| Article | Year |
|---|---|
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Computed Tomography Angiography; Coronary Angiography; C | 2021 |
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Topics: Biomarkers; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Eicosap | 2013 |
7 other studies available for eicosapentaenoic acid ethyl ester and Dyslipidemias
| Article | Year |
|---|---|
Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients.
Topics: Dyslipidemias; Eicosapentaenoic Acid; Humans; Myocardial Infarction; Risk Reduction Behavior | 2022 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Ei | 2022 |
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Topics: Adult; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Suppl | 2021 |
Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Fema | 2019 |
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
Topics: Atherosclerosis; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Drug Costs; Dyslipi | 2019 |
Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
Topics: Cholesterol; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Fatty Acid | 2016 |
Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Topics: Aged; Aged, 80 and over; Cholesterol; Cholesterol, LDL; Docosahexaenoic Acids; Drug Therapy, Combina | 2016 |